Literature DB >> 35344165

In Vitro Development of Mouse and Human NK Cells from Hematopoietic Progenitor Cells.

Ines Ullmo1, Nahide Koksal1, Heather Y K Ang1, Hugh J M Brady2.   

Abstract

Natural killer (NK) cells are lymphocytes that play an important role at clearing virally infected or cancer cells. Their potential and role in cancer immunotherapy have generated great interest, given the promising results of NK cell adoptive transfer clinical trials. The remaining challenge to bring emerging NK cell immunotherapies to the clinic is to enhance the production of large numbers of functionally competent NK cells ex vivo. Here, we describe two in vitro NK cell development assays using hematopoietic progenitor cells (HPCs), one for human NK cells and one for mouse NK cells. These protocols describe two robust methods that can be utilized for investigation of NK cell development and function.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hematopoietic progenitor cell; In vitro; NK cell differentiation; Natural killer cell; Umbilical cord blood

Mesh:

Year:  2022        PMID: 35344165     DOI: 10.1007/978-1-0716-2160-8_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood.

Authors:  Rima Haddad; Philippe Guardiola; Brigitte Izac; Christelle Thibault; Jerry Radich; Anne-Lise Delezoide; Claude Baillou; François M Lemoine; Jean Claude Gluckman; Françoise Pflumio; Bruno Canque
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

Review 2.  Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function.

Authors:  Elisa Montaldo; Genny Del Zotto; Mariella Della Chiesa; Maria Cristina Mingari; Alessandro Moretta; Andrea De Maria; Lorenzo Moretta
Journal:  Cytometry A       Date:  2013-05-06       Impact factor: 4.355

3.  Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells.

Authors:  Anna Domogala; Michael Blundell; Adrian Thrasher; Mark W Lowdell; J Alejandro Madrigal; Aurore Saudemont
Journal:  Cytotherapy       Date:  2017-04-17       Impact factor: 5.414

4.  An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.

Authors:  Huang Zhu; Dan S Kaufman
Journal:  Methods Mol Biol       Date:  2019

5.  Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells.

Authors:  Bartosz Grzywacz; Nandini Kataria; Magdalena Sikora; Robert A Oostendorp; Elaine A Dzierzak; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

Review 6.  Human natural killer cell development.

Authors:  Aharon G Freud; Michael A Caligiuri
Journal:  Immunol Rev       Date:  2006-12       Impact factor: 12.988

7.  Characteristics of hematopoietic stem cells of umbilical cord blood.

Authors:  Anna Hordyjewska; Łukasz Popiołek; Anna Horecka
Journal:  Cytotechnology       Date:  2014-11-06       Impact factor: 2.058

Review 8.  Developmental and Functional Control of Natural Killer Cells by Cytokines.

Authors:  Yang Wu; Zhigang Tian; Haiming Wei
Journal:  Front Immunol       Date:  2017-08-04       Impact factor: 7.561

9.  OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors.

Authors:  Lara Herrera; Juan Manuel Salcedo; Silvia Santos; Miguel Ángel Vesga; Francisco Borrego; Cristina Eguizabal
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

Review 10.  Natural Killer Cells: Development, Maturation, and Clinical Utilization.

Authors:  Alex M Abel; Chao Yang; Monica S Thakar; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.